June 25, 2009
The U.S. District Court of New Jersey has granted summary judgment against Sanofi-Aventis in favor of Israel’s Teva and to Sandoz and Mayne Pharma (Hospira), establishing that patents for Oxaliplatin (Eloxatin) are not infringed by injection.
Eloxatin is protected by a number of patents: US5,338,874 (Expiry Apr 07,2013) US5,420,319 (Expiry Aug 08,2016) US 5,716,988 (Expiry Aug 07,2015) US 5,290,961 (Expiry Jan 12, 2013) xaliplatin was discovered in 1976 at Nagoya City University in Japan by Professor Yoshinori Kidani, who was granted US4169846 over the drug in 1979. This has now expired. Oxaliplatin is a platinum-based chemotherapy drug that is typically administered in combination with fluorouracil and leucovorin and used to treat colorectal cancer. Eloxatin gained European approval in 1999 and USFDA approval in 2004.
Leave a Comment » | 
Israel, News, Patents, Teva, pharmaceuticals, pharmaceuticals and Biotechnology | 
Permalink
Posted by Dr Michael Factor
June 25, 2009
The Men At Work hit “Down Under is being sued by Music publishing company Larrikin which owns the rights to the “Kookaburra” song, claiming tha the melody that accompanies the line “Kookaburra sits in the old gum tree” is reproduced in “Down Under.”
The problem is that the lawyers for “Down Under” songwriters, Colin Hay and Ron Strykert, and music giants, Sony BMG Music Entertainment, Sony DADC Australia, EMI Songs Australia and EMI Music Publishing are claiming that Larrikin doesn’t actually have copyright to “Kookaburra” but the Australian Girl Guides do.
According to court documents, lawyers for the songwriters and the record companies will argue “the Down Under work does not incorporate the whole or any substantial part of the “Kookaburra work.”
1 Comment | Copyright, News, Opinion, passing off | Permalink
Posted by Dr Michael Factor
